Senseonics (NYSE:SENS) Upgraded at HC Wainwright

Senseonics (NYSE:SENS - Get Free Report) was upgraded by analysts at HC Wainwright to a "buy" rating in a report issued on Monday, Marketbeat.com reports. The firm presently has a $1.10 price target on the stock. HC Wainwright's price objective would suggest a potential upside of 108.33% from the company's current price. HC Wainwright also issued estimates for Senseonics' Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.01) EPS, Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.06) EPS, FY2027 earnings at ($0.03) EPS, FY2028 earnings at ($0.01) EPS and FY2029 earnings at $0.01 EPS.

A number of other equities analysts have also recently commented on the company. Mizuho assumed coverage on Senseonics in a report on Thursday, April 10th. They set an "outperform" rating and a $2.00 target price for the company. Wall Street Zen raised Senseonics to a "sell" rating in a research report on Monday, May 12th.

Senseonics Stock Performance

NYSE:SENS traded down $0.01 during trading hours on Monday, reaching $0.53. The company had a trading volume of 3,769,729 shares, compared to its average volume of 6,754,064. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The firm has a market cap of $345.43 million, a PE ratio of -4.06 and a beta of 0.97. The business's 50 day moving average price is $0.61 and its 200-day moving average price is $0.65. Senseonics has a 1-year low of $0.25 and a 1-year high of $1.40.

Senseonics (NYSE:SENS - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.09). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. During the same period in the previous year, the company posted ($0.07) EPS. Research analysts forecast that Senseonics will post -0.14 EPS for the current year.

Institutional Trading of Senseonics

A number of large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its position in Senseonics by 9.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,339,698 shares of the company's stock worth $1,748,000 after buying an additional 274,842 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Senseonics in the 4th quarter valued at $26,000. Renaissance Technologies LLC acquired a new stake in Senseonics during the 4th quarter worth $720,000. Northern Trust Corp grew its position in Senseonics by 11.2% during the 4th quarter. Northern Trust Corp now owns 1,194,960 shares of the company's stock worth $625,000 after purchasing an additional 120,441 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new position in Senseonics in the fourth quarter valued at $32,000. 12.36% of the stock is owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.